Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark

INTRODUCTION: The sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin has shown reductions in major adverse cardiac events similar to glucagon-like peptide-1 receptor agonists (GLP-1RAs). However, evidence is limited about how these therapies compare regarding overall healthcare resource...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomsen, Reimar W., Christensen, Lotte W. B., Kahlert, Johnny, Knudsen, Jakob S., Ustyugova, Anastasia, Sandgaard, Susanne, Holmgaard, Pia, Ehlers, Lars H., Sørensen, Henrik T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663772/
https://www.ncbi.nlm.nih.gov/pubmed/36315384
http://dx.doi.org/10.1007/s13300-022-01323-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663772/
https://www.ncbi.nlm.nih.gov/pubmed/36315384
http://dx.doi.org/10.1007/s13300-022-01323-y

Ejemplares similares